Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEREOPAC trial in borderline resectable pancreatic adenocarcinoma
2022-501181-22-01Phase 2Authorised
- Sponsor
- Erasmus Hospital
- Start
- Feb 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin, fluorouracil, folinic acid, irinotecan, gemcitabine and 1 more in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Erasmus Hospital. Primary endpoints: R0 resection and Disease-free survival. Planned start Feb 2023; status: authorised.
02
Drugs
oxaliplatinfluorouracilfolinic acidirinotecangemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2022-501181-22-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501181-22-01.